Search - tctmd.com

Displaying 241 - 260 of 667

Sort: Relevancy | Date

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Todd Neale

September 29, 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Yael L. Maxwell

July 12, 2016

News Industry News

Essential Medical Inc. Announces FDA Approval to Begin a U.S. Clinical Trial for the MANTA™ Large Bore Vascular Closure Device

July 08, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

Presentation TVT 2016

Be Prepared! The Management of Vascular Complications After Transfemoral TAVR

Presenter: James M. McCabe

June 16, 2016

Presentation TVT 2016

Step-by-Step: Vascular Screening, Transfemoral Access Techniques, and Percutaneous Closure After TAVR

Presenter: Jonathon M. White

June 16, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

患者在 TAVR 后感染性心内膜炎的死亡率高，应予以更好的预防和治疗

Yael L. Maxwell

June 15, 2016

News Daily News

La Alta Mortalidad que Sobreviene tras una Endocarditis Infecciosa Post-TAVR Justifica Mejores Medidas de Prevención y Tratamiento

Yael L. Maxwell

June 15, 2016

News Daily News

High Mortality Following Infective Endocarditis After TAVR Warrants Better Prevention, Treatment

Yael L. Maxwell

June 15, 2016

Presentation

Incidence, Predictors, and Outcome of Patients Developing Infective Endocarditis (IE) Following Transfemoral TAVR

Presenter: Norman Mangner

June 14, 2016

Advertisement

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

New ‘Rapid Recommendations’ Tackle TAVR in Patients at Low-to-Intermediate Risk

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Essential Medical Inc. Announces FDA Approval to Begin a U.S. Clinical Trial for the MANTA™ Large Bore Vascular Closure Device

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

What TAVR Needs Next . . . and What It’s Getting

Be Prepared! The Management of Vascular Complications After Transfemoral TAVR

Step-by-Step: Vascular Screening, Transfemoral Access Techniques, and Percutaneous Closure After TAVR

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

患者在 TAVR 后感染性心内膜炎的死亡率高，应予以更好的预防和治疗

La Alta Mortalidad que Sobreviene tras una Endocarditis Infecciosa Post-TAVR Justifica Mejores Medidas de Prevención y Tratamiento

High Mortality Following Infective Endocarditis After TAVR Warrants Better Prevention, Treatment

Incidence, Predictors, and Outcome of Patients Developing Infective Endocarditis (IE) Following Transfemoral TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content